Galera Therapeutics Appoints Christopher Degnan as Chief Financial Officer
10 oct. 2019 17h02 HE
|
Galera Therapeutics, Inc.
MALVERN, Penn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary...
Galera Therapeutics Announces Two-Year Tumor Outcomes Data for GC4419
08 oct. 2019 08h00 HE
|
Galera Therapeutics, Inc.
MALVERN, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary...
Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of Avasopasem Manganese at 2019 NCCN Annual Conference
21 mars 2019 10h07 HE
|
Galera Therapeutics, Inc.
MALVERN, Pa., March 21, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting
23 oct. 2018 17h45 HE
|
Galera Therapeutics, Inc.
MALVERN, Penn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)
16 oct. 2018 07h30 HE
|
Galera Therapeutics, Inc.
Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application MALVERN, Pa., Oct. 16, 2018 ...
Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication
19 sept. 2018 07h30 HE
|
Galera Therapeutics, Inc.
MALVERN, Pa., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
Galera Therapeutics Presents Structure and Synthesis of GC4419 at American Chemical Society Annual Meeting
20 août 2018 07h30 HE
|
Galera Therapeutics, Inc.
Presentation selected as part of The Halpern Legacy Symposium and press program Phase 3 trial of GC4419 for treatment of severe oral mucositis in patients with head and neck cancer expected to...
Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting
29 juin 2018 08h10 HE
|
Galera Therapeutics, Inc.
GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer Trial investigator Dr. Carryn Anderson honored with...
Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at MASCC/ISOO 2018 Annual Meeting
12 juin 2018 08h00 HE
|
Galera Therapeutics, Inc.
MALVERN, Penn., June 12, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the...
Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
03 juin 2018 11h00 HE
|
Galera Therapeutics, Inc.
GC4419 met primary endpoint, achieving 92 percent reduction in duration of severe oral mucositis (SOM) in patients with head and neck cancer GC4419 also demonstrated reduction in SOM incidence and...